Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years

Parkinson's disease (PD) is a progressive, chronic neurodegenerative disorder. The main neuropathological cause of the disease is the death of dopaminergic neurons in the substantia nigra. Unfortunately, there is no curative treatment yet. The gold-standard of the treatment is levodopa (LD). Du...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Salamon András
Zádori Dénes
Szpisjak László
Klivényi Péter
Vécsei László
Dokumentumtípus: Cikk
Megjelent: 2020
Sorozat:EXPERT OPINION ON PHARMACOTHERAPY 21 No. 18
doi:10.1080/14656566.2020.1806237

mtmt:31543815
Online Access:http://publicatio.bibl.u-szeged.hu/19692
Leíró adatok
Tartalmi kivonat:Parkinson's disease (PD) is a progressive, chronic neurodegenerative disorder. The main neuropathological cause of the disease is the death of dopaminergic neurons in the substantia nigra. Unfortunately, there is no curative treatment yet. The gold-standard of the treatment is levodopa (LD). During the course of the disease, motor complications develop, which postulates the addition of entacapone (ENT) to the dopaminergic medication. Previous studies have suggested that patients have a better quality of life when entacapone is added in a combination with LD.A systematic literature search was performed. Articles were identified through PubMed (MEDLINE), Web of Science, Ovid, and ClinicalTrials.gov databases. The following search terms were used: 'Levodopa' AND 'Carbidopa' OR 'Benserazide' AND 'Entacapone'. The search period was between 2000 and 2020. Twenty randomized and 10 non-randomized clinical trials (12,893 subjects) were included in the qualitative analysis. The systematic review was written in line with the PRISMA guideline.ENT administered in combination with LD resulted in a better quality of life compared to separate tablets. Therefore, in PD patients where impaired motor performance develops and the application of entacapone is necessary, it is suggested to be administered in a single tablet form.
Terjedelem/Fizikai jellemzők:2265-2278
ISSN:1465-6566